Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo

Clinical and Experimental Immunology

Volumn 129, Issue 2, 2002, Pages 198-207

  Harris, C L ^a   Williams, A S ^a   Linton, S M ^a   Morgan, B P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Arthritis; CD59; Complement; Decay accelerating factor; Inflammation

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CIRCULATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HALF LIFE TIME; HEMOLYSIS; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION;

ANIMALS; ANTIGENS, CD55; ARTHRITIS, EXPERIMENTAL; CHO CELLS; COMPLEMENT INACTIVATOR PROTEINS; CRICETINAE; HALF-LIFE; HEMOLYSIS; HUMANS; IMMUNOGLOBULINS; INDICATORS AND REAGENTS; RATS; RECOMBINANT FUSION PROTEINS;

EID: 0036381720     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01924.x     Document Type: Article

References (44)

1. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994; 15:369-96.
2. Morgan BP, Harris CL. Complement Regulatory Proteins. London: Academic Press, 1999.
3. Kinoshita T, Lavoie S, Nussenzweig V. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1). J Immunol 1985; 134:2564-70.
4. Reid KBM, Bentley DR, Campbell RD, Chung LP, Sim RB, Kristensen T, Tack BF. Complement proteins which interact with C3b or C4b. A superfamily of structurally related proteins. Immunol Today 1986; 7:230-4.
5. Morgan BP, Daniels RH, Williams BD. Measurement of Terminal Complement Complexes in Rheumatoid-Arthritis. Clin Exp Immunol 1988; 73:473-8.
6. Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34:1531-7.
7. Oleesky DA, Daniels RH, Williams BD, Amos N, Morgan BP. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions. Clin Exp Immunol 1991; 84:250-5.
8. Thomas TC, Rollins SA, Rother RP et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33:1389-401.
9. Weisman HF, Bartow T, Leppo MK et al. Soluble human complement receptor type 1, in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249:146-51.
10. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin Exp Immunol 2000; 119:210-6.
11. Higgins PJ, Ko JL, Lobell R, Sardonini C, Alessi MK, Yeh CG. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. J Immunol 1997; 158:2872-81.
12. Rushmere NK, Harrison RA, van den Berg CW, Morgan BP. Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochem J 1994; 304:595-601.
13. Hinchliffe SJ, Spiller OB, Rushmere NK, Morgan BP. Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor. J Immunol 1998; 161:5695-703.
14. Charreau B, Cassard A, Tesson L et al. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation 1994; 58: 1222-9.
15. Spiller OB, Harris CL, Morgan BP. Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. J Immunol Meth 1999; 224:51-60.
16. Harris CL, Spiller OB, Morgan BP. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunol 2000; 100:462-70.
17. Morrissey JH. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem 1980; 117:307-10.
18. Kabat LA, Mayer MM. Experimental Immunochemistry, 2nd edition. Springfield, Illinois: Charles C. Thomas, 1961.
19. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978; 80:849-57.
20. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol 1997; 110:45-52.
21. Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995; 5:1888-94.
22. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994; 152:5477-84.
23. Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 1996; 71:173-7.
24. Perry GJ, Eisenberg PR, Zimmerman JL, Levin J. Phase I safety trial of soluble complement receptor type I (TP10) in acute myocardial infarction. J Am Col Cardiol 1998; 31:411A (Abstract).
25. Zimmerman JL, Dellinger RP, Straube RC, Levin JL. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 2000; 28:3149-54.
26. Moran P, Beasley H, Gorrell A et al. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol 1992; 149:1736-43.
27. Christiansen D, Milland J, Thorley BR, McKenzie IF, Mottram PL, Purcell LJ, Loveland BE. Engineering of recombinant soluble CD46: an inhibitor of complement activation. Immunol 1996; 87:348-54.
28. Christiansen D, Milland J, Thorley BR, McKenzie IF, Loveland BE. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Eur J Immunol 1996; 26:578-85.
29. Kroshus TJ, Salerno CT, Yeh CG, Higgins PJ, Bolman RM 3rd, Dalmasso AP. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation. Transplantation 2000; 69:2282-9.
30. Sugita Y, Ito K, Shiozuka K, Suzuki H, Gushima H, Tomita M, Masuho Y. Recombinant soluble CD59 inhibits reactive haemolysis with complement. Immunol 1994; 82:34-41.
31. He C, Alexander JJ, Lim A, Quigg RJ. Production of the rat complement regulator, Crry, as an active soluble protein in Pichia pastoris. Arch Biochem Biophys 1997; 341:347-52.
32. Ashkenazi A, Capon DJ, Ward RHR. Immunoadhesins. Int Rev Immunol 1993; 10:219-29.
33. Byrn RA, Mordenti J, Lucas C et al. Biological properties of a CD4 Immunoadhesin. Nature 1990; 344:667-70.
34. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
35. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19:163-96.
36. Quigg RJ, Kozono Y, Berthiaume D et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998; 160:4553-60.
37. Rehrig S, Fleming SD, Anderson J et al. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol 2001; 167:5921-7.
38. Huang J, Kim LJ, Mealey R, Marsh HC, Zhang Y, Tenner AJ, Connolly ES, Pinsky DJ. Neuronal protection in stroke by an sLe (x)-glycosylated complement inhibitory protein. Science 1999; 285:595-9.
39. Smith GP, Smith RA. Membrane-targeted complement inhibitors. Mol Immunol 2001; 38:249-55.
40. Linton SM, Williams AS, Dodd I, Smith R, Williams BD, Morgan BP. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum 2000; 43:2590-7.
41. Zhang HFYuJ, Bajwa E, Morrison SL, Tomlinson S. Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest 1999; 103:55-61.
42. Zhang H, Lu S, Morrison SL, Tomlinson S. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J Biol Chem 2001; 276:27290-5.
43. Quigg RJ, He C, Hack BK, Alexander JJ, Morgan BP. Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris. Immunol 2000; 99:46-53.
44. Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 1988; 7:1989-94.